PCM
WHWK

Prelude Capital Management’s Whitehawk Therapeutics WHWK Stock Holding History

Prelude Capital Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$35.5K Sell
10,283
-8,513
-45% -$26.7K ﹤0.01% 1144
2025
Q4 		$45.5K Buy
+18,796
New +$43.1K ﹤0.01% 1242
2025
Q2 		– Sell
-10,197
Closed -$18.2K – 1454
2025
Q1 		$18.2K Sell
10,197
-2,700
-21% -$7.05K ﹤0.01% 1132
2024
Q4 		$40.7K Sell
12,897
-4,900
-28% -$11.1K ﹤0.01% 1155
2024
Q3 		$36.7K Sell
17,797
-18,400
-51% -$29.7K ﹤0.01% 1225
2024
Q2 		$52.8K Sell
36,197
-400
-1% -$741 ﹤0.01% 1144
2024
Q1 		$85.6K Buy
36,597
+10,200
+39% +$19.7K ﹤0.01% 1216
2023
Q4 		$53.3K Buy
26,397
+4,500
+21% +$18.9K ﹤0.01% 1072
2023
Q3 		$106K Buy
21,897
+10,823
+98% +$62.9K 0.01% 987
2023
Q2 		$75.7K Buy
+11,074
New +$86.1K ﹤0.01% 953

Other funds holding WHWK

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
KCA
KVP Capital Advisors San Francisco, California $134M AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
YF
Yu Fan $97M AUM 57.2% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

Prelude Capital Management's WHWK Position: Q1 2026 in Review

Prelude Capital Management reduced its Whitehawk Therapeutics (WHWK) stake by 45% in Q1 2026, selling an estimated $26.7K and leaving 10,283 shares worth $35.5K. The position accounts for ﹤0.01% of the portfolio, ranked #1144.

Prelude Capital Management first reported a position in WHWK in Q2 2023 and has held it in 10 quarters since. The position peaked at $106K in Q3 2023. 62 funds tracked by Wall St. Rank hold WHWK as of Q1 2026.

  • Prelude Capital Management held 10,283 shares of Whitehawk Therapeutics worth $35.5K as of Q1 2026.
  • Prelude Capital Management sold 8,513 Whitehawk Therapeutics shares in Q1 2026, an estimated $26.7K.
  • Whitehawk Therapeutics made up ﹤0.01% of Prelude Capital Management's portfolio in Q1 2026, its #1144 holding.
  • Prelude Capital Management first reported a position in Whitehawk Therapeutics in Q2 2023 and has held it in 10 quarters since.
  • Prelude Capital Management's Whitehawk Therapeutics position peaked at $106K in Q3 2023.
  • 62 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q1 2026.

Based on Prelude Capital Management's 13F filing for Q1 2026, filed 15 May 2026.